Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

13
Here, Take Another Hit Of This, Then Sell Some More Aimmune

12h seekingalpha
Once again investors have smoked the strong stuff and sold Aimmune Therapeutics (NASDAQ:AIMT) to levels that underprice its true value and potential. More patient - read thoughtful - investors should find these valuations compelling and an excellent entry point. Aimmune has fallen significantly below its recent secondary offering price of $32 and is currently trading at $27.79 at the time of this writing.
FB DBV GILD DBVT ANAB AIMT NVS KITE PFE SNY

6
Roche's (RHHBY) Xolair Gets Breakthrough Therapy Status

19h zacks
Roche (RHHBY - Free Report) announced that the FDA has granted Breakthrough Therapy designation to Xolair (omalizumab). The designation was granted for the prevention of severe allergic reactions, following accidental exposure to one or more foods in people with allergies, based on data from seven clinical studies evaluating the drug. The studies evaluated Xolair as monotherapy or in combination with oral immunotherapy.
FOX AIMT NVS LMHA LMHB FOXA SNY LM

6
Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold

19h zacks
Amicus Therapeutics (FOLD - Free Report) announced that the FDA has granted accelerated approval to Galafold (migalastat) 123 mg capsules for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.
FOX GILD FOLD LMHA LMHB FOXA SNY LM

5
Alnylam (ALNY) Gets FDA Nod for First-Ever RNAi Therapeutic

19h zacks
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) announced that the FDA has approved Onpattro (patisiran) lipid complex injection- a first-of-its-kind RNA interference (RNAi) therapeutic, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Onpattro is the first and only FDA-approved treatment for this indication.
FOX GILD MDCO LMHA LMHB FOXA ALNY SNY LM

3
Amicus sets US$315,000 price for new Fabry disease treatment - Channel NewsAsia

2018-08-13 channelnewsasia
REUTERS: Amicus Therapeutics priced its new Fabry disease treatment at an average US$315,000 per year in the United States, the company said on Monday.
GCVRZ FOLD SAN SNYNF SNY

4
Amicus sets $315,000 price for new Fabry disease treatment

2018-08-13 reuters
(Reuters) - Amicus Therapeutics priced its new Fabry disease treatment at an average $315,000 per year in the United States, the company said on Monday.
GCVRZ FOLD SAN SNYNF SNY

3
Amicus Receives First FDA Approval For Fabry Disease Treatment In 15 Years

2018-08-13 seekingalpha
Galafold is expected to treat up to 35% to 50% of the Fabry Disease population, those who have the amenable GLA variant.
FOLD SNY

2
Alnylam Receives First Ever FDA Approval For RNAi Therapeutic Treating Rare Disease Making History

2018-08-13 seekingalpha
Alnylam receives FDA approval for the first ever RNAi therapeutic treating patients with a rare disease known as hereditary ATTR amyloidosis.
ABUS ALNY SNY

3
UPDATE 2-Amicus Therapeutics receives U.S. approval for Fabry disease drug

2018-08-11 reuters
(Reuters) - U.S. health regulators on Friday approved Amicus Therapeutics’ Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.
GCVRZ FOLD SAN SNYNF SNY

41
3 Unloved High-Yielders That Will Rise With Rates (and Pay Up to 7% in Cash!)

2018-08-08 investorplace
Once again, almost everyone has gotten sucked in by a tired investor slogan that’s dead wrong—and it’s costing them big gains (and income). But that’s good news for contrarians like us, because we can bank some easy profits thanks to this all-too-predictable reflex.
ARE XKE BXP SNY AMZN BONTQ VZ NVS SPG BONT STAG BMY

3
MannKind: Afrezza Is An A-Fizzle Product

2018-08-07 seekingalpha
A discussion of why flawed data isn't the best way to gain Standard of Care designation for a drug.
MNKD SNY

2
Alnylam's (ALNY) Q2 Loss Wider Than Expected, Sales Beat

2018-08-06 zacks
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) ) incurred a loss of $1.61 per share (excluding stock-based compensation expense), wider than the year ago loss of $1.07 per share and the Zacks Consensus Estimate of a loss of $1.54.
GILD MDCO HZNP ALNY SNY

6
Emergent (EBS) Q2 Earnings and Revenues Surpass Estimates

2018-08-06 zacks
Emergent Biosolutions, Inc. (EBS - Free Report) delivered second-quarter 2018 earnings of $1.07 per share, surpassing the Zacks Consensus Estimate of 96 cents and the year-ago bottom-line figure of 13 cents.
EGRX EBS GSK HZNP GSK BGSF SNY BPL

13
The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis

2018-08-06 zacks
Chicago, IL – August 6, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Pfizer (PFE - Free Report) , Bristol-Myers (BMY - Free Report) , Sanofi (SNY - Free Report) , Glaxo (GSK - Free Report) and Novartis (NVS - Free Report) .
GIII BGSF SNY ADBE ECHO RCKY MTN VNDA MLNX ARW NVS CVLT ADM PFE HUBG HUBOF

4
Avoid Treating Biogen Like a Speculative Drug Stock

2018-08-03 investorplace
Biogen (NASDAQ:BIIB) stock has come down from its recent high. A successful Phase 2 trial of an Alzheimer’s drug sent BIIB stock soaring. However, the stock has pulled back after the company reported its second-quarter results on July 24.
BIIB IONS SNY

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 80105N105